93 unknown. 93 Phase 2, 28 Phase 1, 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 93 | Unknown 93 |
| Phase 1 | 28 | Unknown 28 |
| Phase 3 | 11 | Unknown 11 |
Follow Precursor Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia Inotuzumab ozogamicin - Acute Lymphoid Leukemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2024-07-02 | 2024-07-30 |
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 50 | 2024-04-01 | 2024-04-19 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
| Acute Concussion and Melatonin Melatonin 3 MG, Placebo - Concussion, Mild, Concussion, Brain | Phase 2 | Unknown | Children's National Research Institute | 254 | 2023-03-01 | 2024-02-07 |
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 30 | 2023-01-10 | 2023-06-28 |
| Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) Petiveria Alliacea Preparation, Placebo - Neoplasm, Stomach, Gastric Neoplasms Malignant | Phase 1 / Phase 2 | Unknown | Hospital Universitario San Ignacio | 82 | 2022-12-15 | 2022-10-19 |
| Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL cytarabine+thiotepa+ fludarabine + busulfan - Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 70 | 2022-10-23 | 2022-10-28 |
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase I, Phase II - Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood | Phase 1 / Phase 2 | Unknown | KK Women's and Children's Hospital | 48 | 2022-07-18 | 2023-03-09 |
| Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT VEN+AZA+Modified BUCY - Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 55 | 2022-01-20 | 2023-04-12 |
| Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL Cladribine, Fludarabine - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 32 | 2022-01-01 | 2022-10-13 |
| Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL PTG-CARCIK-CD19 - Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 35 | 2021-12-01 | 2023-05-06 |
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL Navitoclax, Venetoclax - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Israeli Medical Association | 48 | 2021-10-01 | 2021-09-23 |
| Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT boost anti-viral immunity after T-cell depleted HSCT - Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 20 | 2021-09-16 | 2021-10-04 |
| Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT Ex-vivo expanded γδ T cell infusion - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 20 | 2021-09-12 | 2022-03-28 |
| Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy ARI-0001 cells - Acute Lymphoid Leukemia | Phase 2 | Unknown | Sara V. Latorre | 50 | 2021-05-11 | 2024-06-26 |
| Study in Adult Ph-positive ALL Ponatinib, Blinatumomab, Imatinib - Acute Lymphoblastic Leukemia, Adult | Phase 2 | Unknown | Cardiff University | 180 | 2021-01-01 | 2020-12-30 |
| The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China 6-mercaptopurine, Standard treatment, Individualized treatment - Acute Lymphoblastic Leukemia, Pediatric | Phase 2 / Phase 3 | Unknown | Wei Zhao | 82 | 2020-02-01 | 2020-01-14 |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL Car-T Cell Therapy - Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Acibadem University | 24 | 2019-10-12 | 2020-01-27 |
| Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test - Acute Myeloid Leukemia in Remission, Lymphoma in Remission | Phase 2 / Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 227 | 2019-09-16 | 2021-09-28 |
Showing 20 of 93. Sign in to see all of them.
Lymphoma (24) · Leukemia, Myeloid, Acute (20) · Lymphoma, Non-Hodgkin (19) · Burkitt Lymphoma (17) · Leukemia (16) · Lymphoma, Follicular (16) · Lymphoma, Large B-Cell, Diffuse (16) · Leukemia, Lymphocytic, Chronic, B-Cell (15) · Lymphoma, Mantle-Cell (13) · Myelodysplastic Syndromes (13) · Multiple Myeloma (11) · Lymphoma, Large-Cell, Immunoblastic (10) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (10) · Recurrence (10)
Hematologic Diseases (93) · Hemic and Lymphatic Diseases (93) · Immune System Diseases (93) · Immunoproliferative Disorders (93) · Lymphatic Diseases (93) · Lymphoproliferative Disorders (93) · Neoplasms by Histologic Type (93) · Leukemia, Lymphoid (92) · Neoplasms (91) · Leukemia (77) · Pathologic Processes (29) · Pathological Conditions, Signs and Symptoms (29) · Disease Attributes (27) · Leukemia, Myeloid (23) · Chronic Disease (21)
Cyclophosphamide (19) · Cytarabine (15) · Methotrexate (12) · Vincristine (11) · Dexamethasone (10) · Etoposide (8) · Radiotherapy (8) · Busulfan (7) · Doxorubicin (6) · Mercaptopurine (6) · Asparaginase (5) · Immunotherapy, Adoptive (5) · Melphalan (5) · Prednisone (5) · Idarubicin (4)
Nanfang Hospital, Southern Medical University (4) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · Wuhan Sian Medical Technology Co., Ltd (3) · Auxilio Mutuo Cancer Center (2) · Colorado Blood Cancer Institute (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Herbert Irving Comprehensive Cancer Center (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (2) · Medical College of Wisconsin (2) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (2) · Sun Yat-sen University (2) · The First Affiliated Hospital of Soochow University (2) · Acibadem University (1)
China (28) · United States (16) · Germany (6) · Italy (6) · France (5) · Canada (4) · South Korea (4) · Mexico (3) · Belgium (2) · Israel (2) · Puerto Rico (2) · Russia (2) · Sweden (2) · Switzerland (2) · United Kingdom (2)
David G. Savage, MD (2) · Eucario Leon Rodriguez, M.D. (2) · Fernando Cabanillas, MD (2) · Lin Yang, Ph.D. (2) · Monica M Rivera Franco, M.D.,MSc (2) · Qifa Liu, MD (2) · YU HU, M.D., Ph.D (2) · A. Pession (1) · Amir Ali Hamidieh, MD (1) · Andrea Velardi, MD, PhD (1) · Anne Lennard (1) · Chevallier Patrice, MD (1) · Chunji Gao, Professor (1) · David H. Vesole, MD, PhD (1) · Denis-Claude Roy, MD PhD (1)
PMID 28054442, PMID 34515338, PMID 40195173, PMID 41671463, PMID 11675328, PMID 15107815, PMID 16155013, PMID 16564913, PMID 17366834, PMID 18358930, PMID 20371346, PMID 20959411, PMID 21220611, PMID 21846410, PMID 21943236, PMID 22037714, PMID 22074157, PMID 22086414, PMID 22265847, PMID 22323480, PMID 22589701, PMID 23140366, PMID 23244073, PMID 24475787, PMID 24497570, PMID 24641416, PMID 25621950, PMID 25631767, PMID 25682597, PMID 25805929, PMID 25983002, PMID 26687796, PMID 27347147, PMID 27916294, PMID 28161329, PMID 28412099, PMID 28415728, PMID 29506548, PMID 30104718, PMID 30187944, PMID 31409768, PMID 31432232, PMID 31739095, PMID 31819192, PMID 32711004, PMID 33085860, PMID 33184339, PMID 33204013, PMID 33235353, PMID 33462499